Labcorp (LH) announced the FDA has approved its nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic to determine patient eligibility for treatment with BEQVEZ, Pfizer's recently FDA-approved hemophilia B gene therapy. The results from the nAbCyte test will be reported qualitatively as negative or positive. A negative test result indicates that an individual with moderate to severe hemophilia B can be considered for BEQVEZ therapy.
Sonal Bhatia, Head of U.S. Specialty Care Medical Affairs, Pfizer, said: "We believe this companion diagnostic is an important tool for evaluating patients who may be suitable for gene therapy as the treatment paradigm advances with the introduction of gene therapies like BEQVEZ."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.